dna x inc - SONM

SONM

Close Chg Chg %
4.15 0.15 3.61%

Closed Market

4.30

+0.15 (3.61%)

Volume: 14.49K

Last Updated:

Apr 24, 2026, 4:00 PM EDT

Company Overview: dna x inc - SONM

SONM Key Data

Open

$4.04

Day Range

3.75 - 4.42

52 Week Range

2.52 - 38.52

Market Cap

$5.76M

Shares Outstanding

1.49M

Public Float

944.99K

Beta

1.72

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$177.66

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

79.64K

 

SONM Performance

1 Week
 
39.67%
 
1 Month
 
27.74%
 
3 Months
 
-31.76%
 
1 Year
 
-85.98%
 
5 Years
 
-99.66%
 

SONM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About dna x inc - SONM

DNA X, Inc. engages in the provision of rugged and consumer durable mobile devices including phones and accessories designed to provide extra protection for users that demand more durability. It operates through the following geographical segments: the United States, Canada and Latin America, Europe and Middle East, and Asia Pacific. The company was founded by Ram Chandran, Isaac Eteminan, Anush Gopalan, Jai Kumar, Sudu Srinivasan, and Joakim Wiklund on August 5, 1999 and is headquartered in San Diego, CA.

SONM At a Glance

DNA X, Inc.
4445 Eastgate Mall
San Diego, California 92121
Phone 1-650-378-8100 Revenue 0.00
Industry Telecommunications Equipment Net Income -20,657,000.00
Sector Electronic Technology Employees 8
Fiscal Year-end 12 / 2026
View SEC Filings

SONM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -5.614
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.843

SONM Efficiency

Revenue/Employee N/A
Income Per Employee -2,582,125.00
Receivables Turnover N/A
Total Asset Turnover N/A

SONM Liquidity

Current Ratio 0.602
Quick Ratio 0.602
Cash Ratio 0.027

SONM Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -19.023
Return on Equity N/A
Return on Total Capital 292.571
Return on Invested Capital N/A

SONM Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -192.571
Total Debt to Total Assets 11.928
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dna X Inc - SONM

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- 69.83M 93.63M 58.30M
Sales Growth
+27.96% +34.09% -37.74% -100.00%
Cost of Goods Sold (COGS) incl D&A
58.20M 74.31M 48.38M 4.30M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
655.00K 2.21M 3.54M 4.30M
Depreciation
- 642.00K 47.00K 58.00K
Amortization of Intangibles
- - - 13.00K
-
COGS Growth
+22.14% +27.67% -34.90% -91.11%
Gross Income
11.62M 19.32M 9.92M (4.30M)
Gross Income Growth
+68.11% +66.26% -48.66% -143.35%
Gross Profit Margin
- +16.65% +20.64% +17.02%
2022 2023 2024 2025 5-year trend
SG&A Expense
24.86M 18.81M 39.58M 1.11M
Research & Development
- 7.97M 1.77M 14.23M
Other SG&A
16.89M 17.04M 25.35M 1.11M
SGA Growth
-33.79% -24.33% +110.41% -97.21%
Other Operating Expense
- - - -
-
Unusual Expense
- 324.00K 3.98M 161.00K
EBIT after Unusual Expense
(13.56M) 513.00K (33.64M) (5.57M)
Non Operating Income/Expense
(246.00K) (214.00K) 246.00K (902.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
97.00K 15.00K 29.00K 1.49M
Interest Expense Growth
- -84.54% +93.33% +5,024.14%
Gross Interest Expense
97.00K 15.00K 29.00K 1.49M
Interest Capitalized
- - - -
-
Pretax Income
(13.90M) 284.00K (33.42M) (7.96M)
Pretax Income Growth
+63.85% +102.04% -11,868.31% +76.20%
Pretax Margin
- -19.91% +0.30% -57.33%
Income Tax
- 184.00K 374.00K 226.00K
Income Tax - Current - Domestic
- 21.00K 58.00K 13.00K
Income Tax - Current - Foreign
- 306.00K 250.00K 223.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- (143.00K) 66.00K (10.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(14.09M) (90.00K) (33.65M) (7.96M)
Minority Interest Expense
- - - -
-
Net Income
(14.09M) (90.00K) (33.65M) (7.96M)
Net Income Growth
+63.53% +99.36% -37,286.67% +76.36%
Net Margin Growth
- -20.17% -0.10% -57.72%
Extraordinaries & Discontinued Operations
- - - (12.70M)
-
Discontinued Operations
- - - (12.70M)
-
Net Income After Extraordinaries
(14.09M) (90.00K) (33.65M) (20.66M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(14.09M) (90.00K) (33.65M) (20.66M)
EPS (Basic)
-87.7716 -0.3888 -128.3692 -28.5835
EPS (Basic) Growth
+88.05% +99.56% -32,916.77% +77.73%
Basic Shares Outstanding
160.50K 231.61K 262.12K 722.69K
EPS (Diluted)
-87.7716 -0.3888 -128.3692 -28.5835
EPS (Diluted) Growth
+88.05% +99.56% -32,916.77% +77.73%
Diluted Shares Outstanding
160.50K 231.61K 262.12K 722.69K
EBITDA
(12.58M) 2.72M (26.12M) (1.11M)
EBITDA Growth
+55.86% +121.61% -1,060.54% +95.77%
EBITDA Margin
- -18.02% +2.90% -44.80%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 144.00
Number of Ratings 2 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -10.97 Median PE on CY Estimate N/A
Year Ago Earnings -28.58 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Dna X Inc in the News